BackgroundThe cytochrome P450s-mediated metabolic resistance and the target site insensitivity caused by the knockdown resistance ( kdr) mutation in the voltage-gated sodium channel ( vgsc) gene were the main mechanisms conferring resistance to deltamethrin in Culex quinquefasciatus from Thailand. This study aimed to investigate the expression levels of cytochrome P450 genes and detect mutations of the vgsc gene in deltamethrin-resistant Cx. quinquefasciatus populations in Thailand.
MethodsTwo field-collected strains of Cx. quinquefasciatus, Cq_SP and Cq_NiH, were selected with deltamethrin to generate the resistant strains Cq_SP-R and Cq_NiH-R, respectively. Bioassays were tested on larvae and adults of each strain according to WHO methods. Eight cytochrome P450 genes were analyzed for the expression level using quantitative real time-PCR. The cDNA of mosquitoes was amplified and sequenced for four fragments of vgsc gene. The kdr L1014F mutation and the haplotype of the CYP9M10 gene were detected in survivor and dead mosquitoes after exposure to the deltamethrin WHO test paper. Statistical analyses were performed using Fisher’s exaction test.
ResultsBioassay tests revealed a significantly higher resistance level in Cq_SP-R than in Cq_NiH-R strains in both larvae and adults. All eight cytochrome P450 genes were significantly overexpressed in larvae of Cq_NiH-R strain compared to the parent and susceptible Cq_Sus strains. The CYP6AA7 and CYP9J34 genes had the highest expression ratios, exceeding 24-fold in Cq_NiH-R larvae. In Cq_SP-R strain, the CYP4H34 and CYP9J34 genes were overexpressed in both stages. The kdr L1014F mutation was found in Cq_SP-R and its parent Cq_SP strains with a significantly higher mutant allele frequency in the survivor mosquitoes than in dead mosquitoes ( P < 0.0001). The V240M and novel L925F mutations were found only in Cq_SP-R strain. Heterozygous genotype for the D-Cu(+)/Cu(-) of CYP9M10 gene was detected in Cq_NiH and Cq_NiH-R strains but other strains were mostly homozygous for the Cu(-)/Cu(-).
ConclusionsOverexpression of multiple cytochrome P450 genes alone has a relatively minor impact on resistance. The combined mechanisms of cytochrome P450- and kdr-mediated resistance result in significantly higher resistance to deltamethrin in Cx. quinquefasciatus. This study supports sustainable public health initiatives in Thailand to address the evolving challenges of insecticide resistance.
Full list of author information is available at the end of the article
SC contributed to methodology, investigation and original draft writing. BK work on methodology and JS conducted investigation. Additionally, WN, NL and PS contributed to the writing-review and editing. J.Y. was involved in conceptualization, methodology, investigation, formal analysis, original draft writing, writing-review and editing, supervision, project administration, and funding acquisition. All the authors have read and approved the final manuscript.
Saowanee Chamnanya,Benyapa Kiddela,Jassada Saingamsook,et al. Overexpression of multiple cytochrome P450 genes with and without knockdown resistance mutations confers high resistance to deltamethrin in Culex quinquefasciatus [J]. Infect Dis Poverty,2025,14(01):38-49.
DOI:10.1186/s40249-024-01269-2© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1 .0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Primer name | Primer sequence (5′-3′) a | PCR product size (bp) | Domain region in VGSC protein |
---|---|---|---|
Cq_IS2-IS6_F | AGTGATGGCGCGAGGTTTCA | 790 | IS2-IS6 |
Cq_IS2-IS6_R | TTTCGCTGCGGCCGCTTCTT | ||
Cq_IIS1-IIS6_F | ACGAGGACGGTCCGACGTTCAA | 970 | IIS1-IIS6 |
Cq_IIS1-IIS6_R | TGCACGGACGCAATCTGGCT | ||
Cq_IIIS1-IIIS6_F | AGAAAAGCGCGACGCCAGCA | 956 | IIIS1-IIIS6 |
Cq_IIIS1-IIIS6_R | TGTTGGTTTCGCGGATGGGC | ||
Cq_IVS1-IVS6_F | AAGAAGGCTGGGGGATCGCT | 974 | IVS1-IVS6 |
Cq_IVS1-IVS6_R | TCCGGATCGAACTGCTGCCA |
a Primers for amplifying the Cx. quinquefasciatus- vgsc gene fragments were designed using sequences from the Johannesburg strain of Cx. quinquefasciatus, VectorBase Transcript ID CPIJ007595 [ 25 ]. Four pairs of specific primers were designed to encompass the VGSC protein region (domain I-IV) with putative non-synonymous mutations of the Cx. quinquefasciatus-vgsc gene [ 26 ] and used to amplify the DNA fragments.
Mosquito strains | Larval bioassay a | Adult bioassay c | ||||
---|---|---|---|---|---|---|
LC 50 (µg/L) (tested number) | χ 2 (df) | Slope (± SE) | RR b | Deltamethrin %Mortality (tested number) | Permethrin %Mortality (tested number) | |
Cq_SP | 0.440 ( n = 700) | 1.000 (4) | 2.21 (± 0.09) | 55.0 | 26.5 ( n = 162) | 52.9 ( n = 153) |
Cq_SP-R | 2.530 ( n = 700) | 1.000 (3) | 1.77 (± 0.11) | 316.2 | 0.0 ( n = 116) | 18.2 ( n = 122) |
Cq_NiH | 0.080 ( n = 700) | 1.000 (3) | 2.32 (± 0.09) | 10.0 | 55.0 ( n = 300) | 71.0 ( n = 389) |
Cq_NiH-R | 0.480 ( n = 700) | 1.000 (2) | 3.10 (± 0.08) | 60.0 | 16.1 ( n = 186) | 44.3 ( n = 210) |
Cq_Sus | 0.008 ( n = 700) | 1.000 (3) | 1.41 (± 0.14) | 1.0 | 98.6 ( n = 144) | 100.0 ( n = 128) |
a Larval mosquitoes were tested with deltamethrin.
Stage of mosquito | Transcript ID a | Gene | Relative gene expression ± SE b | Ratio c | P-value d | |
---|---|---|---|---|---|---|
Cq_SP (parental strain) | Cq_SP-R (selected strain) | |||||
Cytochrome P450 genes involved in up-regulation | ||||||
Larva | CPIJ011127 | CYP4H34* # | 0.16 ± 0.08 | 0.93 ± 0.03 | 5.9 | < 0.0001 |
CPIJ005959 | CYP6AA7* | 0.82 ± 0.08 | 1.78 ± 0.03 | 2.2 | < 0.0001 | |
CPIJ005955 | CYP6P14* | 1.78 ± 0.08 | 3.84 ± 0.02 | 2.2 | < 0.0001 | |
CPIJ012470 | CYP9AL1* | 0.44 ± 0.07 | 1.61 ± 0.06 | 3.6 | < 0.0001 | |
CPIJ010546 | CYP9J34* # | 0.41 ± 0.09 | 2.99 ± 0.05 | 7.3 | < 0.0001 | |
CPIJ010537 | CYP9J45* | 0.20 ± 0.07 | 0.62 ± 0.05 | 3.2 | < 0.0001 | |
CPIJ014218 | CYP9M10* | 0.10 ± 0.11 | 0.55 ± 0.08 | 5.5 | < 0.0001 | |
Adult | CPIJ011127 | CYP4H34 # | 0.24 ± 0.05 | 0.98 ± 0.05 | 4.0 | < 0.0001 |
CPIJ010546 | CYP9J34 # | 0.16 ± 0.06 | 0.77 ± 0.07 | 4.9 | < 0.0001 | |
Cytochrome P450 genes involved in down-regulation | ||||||
Larva | CPIJ018943 | CYP4C52v1 | 19.18 ± 0.06 | 14.84 ± 0.07 | − 1.3 | < 0.0001 |
Adult | CPIJ018943 | CYP4C52v1 | 0.72 ± 0.13 | 0.09 ± 0.04 | − 8.1 | < 0.0001 |
CPIJ005959 | CYP6AA7 | 2.79 ± 0.10 | 0.44 ± 0.05 | − 6.4 | < 0.0001 | |
CPIJ005955 | CYP6P14 | 2.36 ± 0.11 | 0.42 ± 0.04 | − 5.6 | < 0.0001 | |
CPIJ012470 | CYP9AL1 | 0.56 ± 0.09 | 0.19 ± 0.04 | − 2.9 | < 0.0001 | |
CPIJ010537 | CYP9J45 | 1.56 ± 0.07 | 0.06 ± 0.05 | − 25.2 | < 0.0001 | |
CPIJ014218 | CYP9M10 | 0.36 ± 0.10 | 0.14 ± 0.04 | − 2.5 | < 0.0001 |
a The transcript ID number from the vectorbase of the Cx. quinquefasciatus genome sequence (http://cquinquefasciatus.vectorbase.org/)
Stage of mosquito | Transcript ID a | Gene | Relative gene expression ± SE b | Ratio c | P-value d | |
---|---|---|---|---|---|---|
Cq_NiH (parental strain) | Cq_NiH-R (resistant strain) | |||||
Cytochrome P450 genes involved in up-regulation | ||||||
Larva | CPIJ018943 | CYP4C52v1 | 1.26 ± 0.04 | 2.49 ± 0.07 | 2.0 | < 0.0001 |
CPIJ011127 | CYP4H34* # | 0.39 ± 0.06 | 1.99 ± 0.05 | 5.1 | < 0.0001 | |
CPIJ005959 | CYP6AA7* # | 0.41 ± 0.05 | 9.92 ± 0.06 | 24.2 | < 0.0001 | |
CPIJ005955 | CYP6P14* # | 0.57 ± 0.05 | 10.43 ± 0.05 | 18.2 | < 0.0001 | |
CPIJ012470 | CYP9AL1* # | 0.64 ± 0.06 | 1.82 ± 0.06 | 2.8 | < 0.0001 | |
CPIJ010546 | CYP9J34* | 0.63 ± 0.09 | 15.11 ± 0.07 | 24.1 | < 0.0001 | |
CPIJ010537 | CYP9J45* # | 0.74 ± 0.05 | 3.41 ± 0.07 | 4.6 | < 0.0001 | |
CPIJ014218 | CYP9M10* # | 0.39 ± 0.05 | 1.49 ± 0.04 | 3.8 | < 0.0001 | |
Adult | CPIJ018943 | CYP4C52v1 | 0.95 ± 0.08 | 1.51 ± 0.09 | 1.6 | < 0.0001 |
CPIJ005959 | CYP6AA7 # | 0.28 ± 0.06 | 3.60 ± 0.06 | 13.0 | < 0.0001 | |
CPIJ005955 | CYP6P14 # | 0.72 ± 0.08 | 12.94 ± 0.08 | 18.0 | < 0.0001 | |
CPIJ012470 | CYP9AL1 # | 0.91 ± 0.08 | 2.42 ± 0.09 | 2.7 | < 0.0001 | |
CPIJ010537 | CYP9J45 # | 0.31 ± 0.06 | 2.26 ± 0.07 | 7.3 | < 0.0001 | |
CPIJ014218 | CYP9M10 # | 1.10 ± 0.06 | 4.11 ± 0.08 | 3.7 | < 0.0001 | |
Cytochrome P450 genes involved in down-regulation | ||||||
Adult | CPIJ011127 | CYP4H34 | 4.08 ± 0.07 | 2.68 ± 0.08 | − 1.5 | < 0.0001 |
CPIJ010546 | CYP9J34 | 4.95 ± 0.06 | 2.80 ± 0.06 | − 1.8 | < 0.0001 |
a The transcript ID number from the vectorbase of the Cx. quinquefasciatus genome sequence (http://cquinquefasciatus.vectorbase.org/)
vgsc mutation | No. of tested | Genotype frequency, n (%) | Allele frequency (%) | |||
---|---|---|---|---|---|---|
Homozygous wild type | Heterozygous | Homozygous mutant | Wild type | Mutant | ||
V240M | 6 | 0 (0.0) | 4 (66.7) | 2 (33.3) | 33.3 | 66.7 |
L925F | 6 | 0 (0.0) | 6 (100.0) | 0 (0.0) | 50.0 | 50.0 |
L1014F | 6 | 0 (0.0) | 0 (0.0) | 6 (100.0) | 0.0 | 100.0 |
Strain | Status | No. of tested | kdr L1014F genotyping No. of mosquitoes (% frequency) | Allele frequency (%) | P-value | |||
---|---|---|---|---|---|---|---|---|
L/L | L/F | F/F | L | F | ||||
Cq_SP | Survivor | 26 | 7 (26.9) | 4 (15.4) | 15 (57.7) | 35.0 | 65.0 | < 0.0001* |
Dead | 20 | 15 (75.0) | 2 (10.0) | 3 (15.0) | 80.0 | 20.0 | ||
Total | 46 | 22 (47.8) | 6 (13.1) | 18 (39.1) | 54.0 | 46.0 | ||
Cq_SP-R | Survivor | 39 | 2 (5.1) | 3 (7.7) | 34 (87.2) | 9.0 | 91.0 | ND |
Dead | 0 | ND | ND | ND | ND | ND | ||
Total | 39 | 2 (5.1) | 3 (7.7) | 34 (87.2) | 9.0 | 91.0 | ||
Cq_NiH | Survivor | 23 | 23 (100.0) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | 1.000 |
Dead | 24 | 24 (100.0) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | ||
Total | 47 | 47 (100) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | ||
Cq_NiH-R | Survivor | 17 | 17 (100) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | 1.000 |
Dead | 17 | 17 (100) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | ||
Total | 34 | 34 (100) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | ||
Cq_Sus | Survivor | 2 | 2 (100.0) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | 1.000 |
Dead | 34 | 34 (100.0) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 | ||
Total | 36 | 36 (100.0) | 0 (0.0) | 0 (0.0) | 100.0 | 0.0 |
*The mutant F allele showed significantly higher frequencies in survivor mosquitoes than those in dead mosquitoes ( P < 0.0001) using Fisher’s exaction test. L and F are concatenated bases representing leucine and phenylalanine, respectively
Strain | Status | No. of tested | CYP9M10 genotyping No. of mosquitoes (% frequency) | |
---|---|---|---|---|
Cu(−)/Cu(−) | D-Cu(+)/Cu(−) | |||
Cq_SP | Survivor | 17 | 17 (100.0) | 0 (0.0) |
Dead | 18 | 18 (100.0) | 0 (0.0) | |
Total | 35 | 35 (100.0) | 0 (0.0) | |
Cq_SP-R | Survivor | 24 | 24 (100.0) | 0 (0.0) |
Dead | 0 | ND | ND | |
Total | 24 | 24 (100.0) | 0 (0.0) | |
Cq_NIH | Survivor | 24 | 21 (87.5) | 3 (12.5) |
Dead | 6 | 5 (83.4) | 1 (16.6) | |
Total | 30 | 26 (86.7) | 4 (13.3) | |
Cq_NIH-R | Survivor | 19 | 16 (84.2) | 3 (15.8) |
Dead | 17 | 17 (100.0) | 0 (0.0) | |
Total | 36 | 33 (91.7) | 3 (8.3) | |
Cq_Sus | Survivor | 2 | 2 (100.0) | 0 (0.0) |
Dead | 22 | 22 (100.0) | 0 (0.0) | |
Total | 24 | 24 (100.0) | 0 (0.0) |
Cu(-), CuRE1 non-inserted (wild type); D-Cu(+), CuRE1-inserted and duplicated (strong type).
Full list of author information is available at the end of the article
SC contributed to methodology, investigation and original draft writing. BK work on methodology and JS conducted investigation. Additionally, WN, NL and PS contributed to the writing-review and editing. J.Y. was involved in conceptualization, methodology, investigation, formal analysis, original draft writing, writing-review and editing, supervision, project administration, and funding acquisition. All the authors have read and approved the final manuscript.

你好,我可以帮助您更好的了解本文,请向我提问您关注的问题。